Literature DB >> 25770305

Treatment of vulvovaginal candidiasis: a review of the literature.

Andraž Dovnik1, Andrej Golle2, Dušan Novak2, Darja Arko3, Iztok Takač4.   

Abstract

Vulvovaginal candidiasis (VVC) affects around three-quarters of all women during their reproductive age, although the exact incidence of VVC is difficult to determine because many patients are self-treated. The infections are divided into complicated and uncomplicated. Uncomplicated VVC is most effectively treated with local azoles. Oral treatment with a single dose of fluconazole is also effective for treating uncomplicated VVC. Treatment of complicated VVC is prolonged and most commonly consists of multiple doses of oral fluconazole or at least 1 week of local azoles. The role of probiotics in treating VVC is still disputed. This article presents a review of the literature on the various treatment options for VVC. Treatment for the most common pathogens that cause complicated VVC is also discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25770305     DOI: 10.15570/actaapa.2015.2

Source DB:  PubMed          Journal:  Acta Dermatovenerol Alp Pannonica Adriat        ISSN: 1318-4458


  13 in total

1.  Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation.

Authors:  Mariana Robatto; Maria Clara Pavie; Igor Garcia; Manoela Porto Menezes; Milena Bastos; Handerson Jorge Dourado Leite; Andreia Noites; Patrícia Lordelo
Journal:  Lasers Med Sci       Date:  2019-04-03       Impact factor: 3.161

Review 2.  Role of Vaginal Mucosa, Host Immunity and Microbiota in Vulvovaginal Candidiasis.

Authors:  Subatrra Nair Balakrishnan; Haizat Yamang; Michael C Lorenz; Shu Yih Chew; Leslie Thian Lung Than
Journal:  Pathogens       Date:  2022-05-25

3.  Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504).

Authors:  S Palacios; J Espadaler; J M Fernández-Moya; C Prieto; N Salas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-09       Impact factor: 3.267

4.  Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications.

Authors:  Wenli Feng; Jing Yang; Lu Yang; Qing Li; Xin Zhu; Zhiqin Xi; Zusha Qiao; Wen Cen
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447

5.  Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study.

Authors:  Xianling Zeng; Yafei Zhang; Taohong Zhang; Yan Xue; Huiqiu Xu; Ruifang An
Journal:  Biomed Res Int       Date:  2018-06-07       Impact factor: 3.411

6.  Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis.

Authors:  Fen Qin; Quan Wang; Chunlian Zhang; Caiyun Fang; Liping Zhang; Hailin Chen; Mi Zhang; Fei Cheng
Journal:  Infect Drug Resist       Date:  2018-10-17       Impact factor: 4.003

7.  Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis.

Authors:  Hong Liao; Shanling Liu; He Wang; Hang Su; Zhenjun Liu
Journal:  BMC Microbiol       Date:  2019-01-08       Impact factor: 3.605

8.  Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae.

Authors:  Seyed Ebrahim Hashemi; Tahereh Shokohi; Mahdi Abastabar; Narges Aslani; Mahbobeh Ghadamzadeh; Iman Haghani
Journal:  Curr Med Mycol       Date:  2019

Review 9.  Role of female intimate hygiene in vulvovaginal health: Global hygiene practices and product usage.

Authors:  Ying Chen; Elizabeth Bruning; Joseph Rubino; Scott E Eder
Journal:  Womens Health (Lond)       Date:  2017-09-22

10.  Evaluating the accuracy and diagnostic value of CFW and a new fluorescent reagents, fluorescent brightener 85, for the diagnosis of vulvovaginal candidiasis.

Authors:  Yunzhuan Zhao; Zixuan Yu; Xueping Yue
Journal:  J Clin Lab Anal       Date:  2021-07-12       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.